In conclusion, our results demonstrate that biomarker-based models, particularly BALAD-2, offer superior prognostic accuracy compared with traditional BCLC staging, individual biomarkers (AFP, AFP-L3%, and DCP), and liver function scores (Child–Pugh, MELD, and ALBI) in patients with HCC. The gene discussed is AFP; the disease is hepatocellular carcinoma.